sanofiaventis-acquires-controlling-stake-in-shantha

Sanofi-aventis acquires controlling stake in Shantha

The French pharmaceuticals company agrees to an aggressive valuation of $784 million to buy control of the Hyderabad-based biotechnology firm from Merieux Alliance.

Sanofi-aventis will acquire a controlling interest in Hyderabad-based vaccine company Shantha Biotechnics at a price which values the Indian company at 550 million $784 million.

Sanofi Pasteur, the vaccines division of Sanofi-aventis, has signed an agreement with Merieux Alliance to buy Merieux's subsidiary ShanH, which in turn owns around an 80% stake in Shantha.

Shantha, which is not listed, is expected to have revenues of $90 million for the current fiscal year, and based on that, the agreed price translates into a firm value-to-sales multiple of 8.7 times. Sanofi-aventis is paying for the growth potential of Shantha, which has seen its sales multiply by 13 times from a revenue of Rs324 million...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222